In conclusion, ibrutinib effectively attenuated amyloidogenesis, tau hyperphosphorylation, and microglia/astrocyte-associated neuroinflammation in the early-phase AD mouse model, consistent with our previous findings [4]. Here, MAPT is linked to Alzheimer disease.